OMERS ADMINISTRATION Corp Buys New Position in Merus (NASDAQ:MRUS)

OMERS ADMINISTRATION Corp acquired a new position in Merus (NASDAQ:MRUS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,600 shares of the biotechnology company's stock, valued at approximately $446,000.

A number of other hedge funds have also made changes to their positions in MRUS. Wells Fargo & Company MN raised its stake in shares of Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 300 shares in the last quarter. Avior Wealth Management LLC bought a new stake in Merus in the 4th quarter valued at $76,000. Lazard Asset Management LLC acquired a new stake in shares of Merus during the 4th quarter valued at about $84,000. Public Employees Retirement Association of Colorado acquired a new stake in shares of Merus during the 4th quarter valued at about $146,000. Finally, Tudor Investment Corp ET AL bought a new stake in Merus in the fourth quarter valued at about $213,000. Institutional investors and hedge funds own 96.14% of the company's stock.

Merus Price Performance

MRUS stock traded down $1.61 during midday trading on Thursday, reaching $41.60. 1,821,344 shares of the stock were exchanged, compared to its average volume of 731,960. Merus has a 52 week low of $33.19 and a 52 week high of $61.61. The company has a fifty day moving average price of $42.65 and a 200 day moving average price of $43.60. The stock has a market capitalization of $2.88 billion, a PE ratio of -10.53 and a beta of 0.94.

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. As a group, analysts anticipate that Merus will post -3.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

MRUS has been the topic of several analyst reports. Bank of America lowered their target price on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a report on Monday, March 10th. HC Wainwright reaffirmed a "buy" rating and set a $85.00 price target on shares of Merus in a research note on Monday, March 3rd. William Blair reaffirmed an "outperform" rating on shares of Merus in a report on Monday, April 28th. Needham & Company LLC restated a "buy" rating and set a $75.00 target price on shares of Merus in a research report on Monday. Finally, Wells Fargo & Company lowered their price objective on shares of Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $84.54.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.